In 2016, the phase 2 KEYNOTE–021 trial first demonstrated that 1st–line pembrolizumab plus chemotherapy achieved superior efficacy over chemotherapy (ORR, 55% vs. 29%) for patients with non–squamous NSCLC with/without PD–L1 expression (57). The gene discussed is CD274; the disease is non-small cell lung carcinoma.